Broader anti-EBV TCR repertoire in multiple sclerosis: disease specificity and treatment modulation - Top-Institutions - MDSpire

Broader anti-EBV TCR repertoire in multiple sclerosis: disease specificity and treatment modulation

  • By

  • Tilman Schneider-Hohendorf

  • Christian Wünsch

  • Simon Falk

  • Catarina Raposo

  • Florian Rubelt

  • Hamid Mirebrahim

  • Hosseinali Asgharian

  • Ulrich Schlecht

  • Daniel Mattox

  • Wenyu Zhou

  • Eva Dawin

  • Marc Pawlitzki

  • Sarah Lauks

  • Sven Jarius

  • Brigitte Wildemann

  • Joachim Havla

  • Tania Kümpfel

  • Miriam-Carolina Schrot

  • Marius Ringelstein

  • Markus Kraemer

  • Carolin Schwake

  • Thomas Schmitter

  • Ilya Ayzenberg

  • Katinka Fischer

  • Sven G Meuth

  • Orhan Aktas

  • Martin W Hümmert

  • Julian R Kretschmer

  • Corinna Trebst

  • Ilka Kleffner

  • Jennifer Massey

  • Paolo A Muraro

  • Haiyin Chen-Harris

  • Catharina C Gross

  • Luisa Klotz

  • Heinz Wiendl

  • Nicholas Schwab

  • July 18, 2024

  • 0 min

Share

Top Institutions in Neurology

Brief introduction explaining scope and methodology.

  • #1

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Neurology
    • Immunology
    • Multiple Sclerosis Research

  • #2

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Neurology
    • Neuroimmunology
    • Multiple Sclerosis

  • #3

    Karolinska Institutet
    Karolinska Institutet

    Stockholm, N/A

    Key Differentiators

    • Neurology
    • Immunology
    • Multiple Sclerosis Research

  • #4

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Neurology
    • Immunology
    • Multiple Sclerosis

  • #5

    University of Cambridge
    University of Cambridge

    Cambridge, N/A

    Key Differentiators

    • Neurology
    • Immunology
    • Multiple Sclerosis Research

Original Source(s)

Broader anti-EBV TCR repertoire in multiple sclerosis: disease specificity and treatment modulation

  • by Tilman Schneider-Hohendorf, Christian Wünsch, Simon Falk, Catarina Raposo, Florian Rubelt, Hamid Mirebrahim, Hosseinali Asgharian, Ulrich Schlecht, Daniel Mattox, Wenyu Zhou, Eva Dawin, Marc Pawlitzki, Sarah Lauks, Sven Jarius, Brigitte Wildemann, Joachim Havla, Tania Kümpfel, Miriam-Carolina Schrot, Marius Ringelstein, Markus Kraemer, Carolin Schwake, Thomas Schmitter, Ilya Ayzenberg, Katinka Fischer, Sven G Meuth, Orhan Aktas, Martin W Hümmert, Julian R Kretschmer, Corinna Trebst, Ilka Kleffner, Jennifer Massey, Paolo A Muraro, Haiyin Chen-Harris, Catharina C Gross, Luisa Klotz, Heinz Wiendl, Nicholas Schwab

  • July 18, 2024

Related Content

Long-Term Outcomes of Ublituximab Treatment in Multiple Sclerosis: Findings from the ULTIMATE I and II Open-Label Extension Trials

Loss of oligodendrocyte transcription factor 2 protein expression in metabolically stressed oligodendrocytes

The quality of life in Ecuadorian patients with multiple sclerosis and neuromyelitis optica spectrum disorder and their association with anxiety, depression, fatigue, and disability